CEO COMMENT During the third quarter, we received our first recurring order for NLAB Saga® at a value of SEK 3.7 million from a customer in China. After the end of the quarter, we also received a supplementary order worth SEK 1.9 million from this customer, who is a producer of the fast-growing drug class GLP-1 analogues among other things. This is solid proof that NLAB Saga® works just as well as we expected also
We have now produced a number of consecutive large-scale batches within specifications which has enabled us to build up a stock of products for sale. We have also received our first slightly larger order for NLAB Saga® and we are now intensifying our sales efforts. It is very gratifying that the systematic work to further develop the large-scale production of our silica media NLAB Saga® has borne fruit – the plant now delivers significantly larger
The year has started both positively and negatively. On a positive note, we have started delivering chromatography media to customers and we achieved net sales of MSEK 5 in the first quarter. This is the company’s highest sales of chromatography products in a single quarter to date and in line with the expectations of a a sharp increase in sales of chromatography media in 2024. At the same time, the work of optimizing the production
2023 has been marked by geopolitical tensions and macroeconomic uncertainty. Like most others, Nanologica has been affected by this and we have had to prioritize our resources. On the other hand, we operate in a market segment that is virtually insensitive to economic cycles. We expect a commercial breakthrough in the near future and have a clear growth strategy for how we can capitalize on the strong market growth that exists in drugs for the
CEO COMMENT During the last quarter of the year, Nanologica took clear steps forward. The production problems we have wrestled with during the year have now been handled and several deliveries to customers have been made. After rigorous testing of our silica-based purification media NLAB Saga®, we made a delivery in October to one of the world’s largest insulin manufacturers in Asia against an order we received in 2022. We have been determined to ensure
DELIVERY OF SILICA TO INSULIN MANUFACTURER IN ASIA We have now delivered silica against the order we received last year from one of the world’s largest insulin manufacturers in Asia. This means that we are taking a big step towards establishing ourselves as a recognized supplier of high-quality silica for the purification of peptides. The delivery has taken longer time than expected as we wanted to be certain that the silica we deliver has the
